Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1990 Sep;212(3):295–307. doi: 10.1097/00000658-199009000-00008

Liver, kidney, and thoracic organ transplantation under FK 506.

S Todo 1, J J Fung 1, T E Starzl 1, A Tzakis 1, A J Demetris 1, R Kormos 1, A Jain 1, M Alessiani 1, S Takaya 1, R Shapiro 1
PMCID: PMC1358160  PMID: 1697743

Abstract

The new immunosuppressive drug FK 506 was used from the outset with low doses of prednisone to treat 120 recipients of primary liver grafts and 20 more patients undergoing liver retransplantation. The patient survival rate after 2 to 8 months in the primary liver transplantation series is 93.3%, with original graft survival of 87.5%. Of the 20 patients in the hepatic retransplant series, 17 (85%) are living. Almost all of the surviving patients have good liver function. In addition 11 hearts, 2 double lungs, and a heart-lung have been transplanted under FK 506, with survival of all 14 patients. With all of the organ systems so far tested, including the kidney (which has been reported elsewhere), rejection usually has been controlled without additional drugs and with lower average steroid doses than in the past. Nephrotoxicity has been observed, but not to an alarming degree, and there has been a notable absence of hypertension. There is a suggestion that serum cholesterol may be lowered by FK 506, but this is unproved. Although the adverse reactions of FK 506 and the immunosuppressive mechanisms resemble those of cyclosporine, our preliminary observations suggest that FK 506 may have a more advantageous therapeutic index.

Full text

PDF
295

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballantyne C. M., Podet E. J., Patsch W. P., Harati Y., Appel V., Gotto A. M., Jr, Young J. B. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989 Jul 7;262(1):53–56. [PubMed] [Google Scholar]
  2. Boudreaux J. P., McHugh L., Canafax D. M., Ascher N., Sutherland D. E., Payne W., Simmons R. L., Najarian J. S., Fryd D. S. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987 Sep;44(3):376–381. doi: 10.1097/00007890-198709000-00010. [DOI] [PubMed] [Google Scholar]
  3. Fischer G., Bang H. The refolding of urea-denatured ribonuclease A is catalyzed by peptidyl-prolyl cis-trans isomerase. Biochim Biophys Acta. 1985 Mar 22;828(1):39–42. doi: 10.1016/0167-4838(85)90006-8. [DOI] [PubMed] [Google Scholar]
  4. Friedman E. A., Shyh T. P., Beyer M. M., Manis T., Butt K. M. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol. 1985;5(3):196–202. doi: 10.1159/000166932. [DOI] [PubMed] [Google Scholar]
  5. Fung J. J., Todo S., Jain A., McCauley J., Alessiani M., Scotti C., Starzl T. E. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc. 1990 Feb;22(1):6–12. [PMC free article] [PubMed] [Google Scholar]
  6. Harding M. W., Galat A., Uehling D. E., Schreiber S. L. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature. 1989 Oct 26;341(6244):758–760. doi: 10.1038/341758a0. [DOI] [PubMed] [Google Scholar]
  7. Kahan B. D. Cyclosporine. N Engl J Med. 1989 Dec 21;321(25):1725–1738. doi: 10.1056/NEJM198912213212507. [DOI] [PubMed] [Google Scholar]
  8. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987 Sep;40(9):1256–1265. doi: 10.7164/antibiotics.40.1256. [DOI] [PubMed] [Google Scholar]
  9. Markus B. H., Dickson E. R., Grambsch P. M., Fleming T. R., Mazzaferro V., Klintmalm G. B., Wiesner R. H., Van Thiel D. H., Starzl T. E. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med. 1989 Jun 29;320(26):1709–1713. doi: 10.1056/NEJM198906293202602. [DOI] [PubMed] [Google Scholar]
  10. Sawada S., Suzuki G., Kawase Y., Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol. 1987 Sep 15;139(6):1797–1803. [PubMed] [Google Scholar]
  11. Siekierka J. J., Hung S. H., Poe M., Lin C. S., Sigal N. H. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989 Oct 26;341(6244):755–757. doi: 10.1038/341755a0. [DOI] [PubMed] [Google Scholar]
  12. Starzl T. E., Demetris A. J. Liver transplantation: a 31-year perspective. Part I. Curr Probl Surg. 1990 Feb;27(2):49–116. doi: 10.1016/0011-3840(90)90021-v. [DOI] [PubMed] [Google Scholar]
  13. Starzl T. E., Demetris A. J., Van Thiel D. Liver transplantation (1). N Engl J Med. 1989 Oct 12;321(15):1014–1022. doi: 10.1056/NEJM198910123211505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Starzl T. E., Fung J. J. Transplantation. JAMA. 1990 May 16;263(19):2686–2687. [PMC free article] [PubMed] [Google Scholar]
  15. Starzl T. E., Fung J., Jordan M., Shapiro R., Tzakis A., McCauley J., Johnston J., Iwaki Y., Jain A., Alessiani M. Kidney transplantation under FK 506. JAMA. 1990 Jul 4;264(1):63–67. [PMC free article] [PubMed] [Google Scholar]
  16. Starzl T. E., Todo S., Fung J., Demetris A. J., Venkataramman R., Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989 Oct 28;2(8670):1000–1004. doi: 10.1016/s0140-6736(89)91014-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tamura K., Kobayashi M., Hashimoto K., Kojima K., Nagase K., Iwasaki K., Kaizu T., Tanaka H., Niwa M. A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc. 1987 Oct;19(5 Suppl 6):23–29. [PubMed] [Google Scholar]
  18. Todo S., Fung J. J., Demetris A. J., Jain A., Venkataramanan R., Starzl T. E. Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc. 1990 Feb;22(1):13–16. [PMC free article] [PubMed] [Google Scholar]
  19. Zeevi A., Duquesnoy R., Eiras G., Rabinowich H., Todo S., Makowka L., Starzl T. E. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc. 1987 Oct;19(5 Suppl 6):40–44. [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES